Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$2.61 -6.1%	$2.18	$0.80 ▼ $3.42	$114.22M	-0.88	131,325 shs	99,008 shs
CMPS COMPASS Pathways	$4.72 -0.8%	$3.96	$2.25 ▼ $8.08	$456.68M	2.17	1.89 million shs	789,147 shs
ETON Eton Pharmaceuticals	$17.28 -1.0%	$15.20	$4.45 ▼ $21.48	$468.23M	1.13	335,744 shs	258,251 shs
PRTC PureTech Health	$18.01 -8.3%	$18.22	$13.30 ▼ $24.99	$473.80M	1.12	3,205 shs	16,808 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	+3.15%	+12.30%	-12.70%	+157.87%	+42.82%
CMPS COMPASS Pathways	+3.93%	+16.38%	+9.93%	+12.80%	-40.50%
ETON Eton Pharmaceuticals	+2.17%	+7.78%	+13.38%	-13.05%	+286.28%
PRTC PureTech Health	-0.23%	+0.25%	-0.46%	+7.28%	-16.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	2.3366 of 5 stars	3.3	3.0	3.3	1.7	0.0
CMPS COMPASS Pathways	2.4238 of 5 stars	3.4	3.0	2.6	0.8	0.6
ETON Eton Pharmaceuticals	2.1604 of 5 stars	3.5	1.0	2.6	1.7	0.6
PRTC PureTech Health	2.9058 of 5 stars	3.8	5.0	3.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	2.50	Moderate Buy	$5.50	110.73% Upside
CMPS COMPASS Pathways	2.86	Moderate Buy	$16.29	245.04% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	71.68% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	149.86% Upside

Current Analyst Ratings Breakdown

Latest ANEB, ETON, PRTC, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $40.00
8/1/2025	CMPS COMPASS Pathways	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
7/23/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/15/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
6/23/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/23/2025	CMPS COMPASS Pathways	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ In-Line	$11.00 ➝ $6.00
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.15 per share	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$1.69 per share	N/A
ETON Eton Pharmaceuticals	$39.01M	11.88	N/A	N/A	$0.89 per share	19.42
PRTC PureTech Health	$4.83M	89.98	$2.19 per share	8.24	$17.04 per share	1.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.20M	-$0.26	N/A	∞	N/A	N/A	-90.11%	-84.53%	9/24/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.84	N/A	N/A	N/A	N/A	-87.89%	-57.77%	10/30/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.16	N/A	34.56	N/A	-7.10%	-0.73%	-0.22%	11/11/2025 (Estimated)
PRTC PureTech Health	$27.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)

Latest ANEB, ETON, PRTC, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/24/2025	Q4 2025	ANEB Anebulo Pharmaceuticals	-$0.05	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ETON Eton Pharmaceuticals	-$0.01	-$0.10	-$0.09	-$0.10	$16.71 million	$18.93 million
7/31/2025	Q2 2025	CMPS COMPASS Pathways	-$0.37	-$0.38	-$0.01	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	25.29	25.29
CMPS COMPASS Pathways	0.16	8.82	8.82
ETON Eton Pharmaceuticals	1.14	1.77	1.16
PRTC PureTech Health	N/A	9.33	9.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
CMPS COMPASS Pathways	46.19%
ETON Eton Pharmaceuticals	27.86%
PRTC PureTech Health	0.04%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
CMPS COMPASS Pathways	3.93%
ETON Eton Pharmaceuticals	16.03%
PRTC PureTech Health	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	41.08 million	7.97 million	Not Optionable
CMPS COMPASS Pathways	120	95.94 million	92.17 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
PRTC PureTech Health	100	24.13 million	22.85 million	Not Optionable

ANEB, ETON, PRTC, and CMPS Headlines

Recent News About These Companies

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Down 39.6% in July

August 21, 2025 | marketbeat.com

PureTech Health: Notice of Half-Yearly Results

August 18, 2025 | businesswire.com

PureTech Health (NASDAQ:PRTC) Trading Up 1.4% - Still a Buy?

August 15, 2025 | marketbeat.com

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

August 13, 2025 | businesswire.com

PureTech Health plc: PureTech Announces Board Change

July 31, 2025 | finanznachrichten.de

PureTech CEO Bharatt Chowrira steps down

July 16, 2025 | thepharmaletter.comT

PureTech Health CEO Bharatt Chowrira Resigns

July 16, 2025 | marketwatch.com

PureTech Announces Leadership Transition

July 16, 2025 | businesswire.com

PureTech Health announces board chair Raju Kucherlapati steps down

July 10, 2025 | investing.com

PureTech Health plc (PRTC) Income Statement - Yahoo Finance

July 9, 2025 | finance.yahoo.com

PureTech Announces Board Change

July 8, 2025 | businesswire.com

Why This Biotech Stock Just Doubled In A Single Day

June 26, 2025 | benzinga.com

PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial

May 22, 2025 | businesswire.com

PureTech’s deupirfenidone shows strong and durable efficacy

May 21, 2025 | thepharmaletter.comT

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

May 9, 2025 | businesswire.com

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

May 1, 2025 | finance.yahoo.com

PureTech to Present Results from Phase 2b ELEVATE…

May 1, 2025 | pharmiweb.comP

PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript

April 30, 2025 | seekingalpha.com

PureTech Announces Annual Results for Year Ended December 31, 2024

April 30, 2025 | businesswire.com

PureTech Health Stock Price, Quotes and Forecasts | NASDAQ:PRTC | Benzinga

April 22, 2025 | benzinga.com

Leerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)

April 10, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB, ETON, PRTC, and CMPS Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$2.61 -0.17 (-6.12%)

Closing price 04:00 PM Eastern

Extended Trading

$2.64 +0.04 (+1.34%)

As of 04:48 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

COMPASS Pathways NASDAQ:CMPS

$4.72 -0.04 (-0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$4.70 -0.02 (-0.42%)

As of 07:19 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Eton Pharmaceuticals NASDAQ:ETON

$17.28 -0.18 (-1.03%)

Closing price 04:00 PM Eastern

Extended Trading

$17.26 -0.03 (-0.14%)

As of 04:10 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

PureTech Health NASDAQ:PRTC

$18.01 -1.62 (-8.25%)

Closing price 03:59 PM Eastern

Extended Trading

$18.60 +0.58 (+3.25%)

As of 04:04 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time